FDA Approves Moderna’s RSV Vaccine, its Second Licensed Product

The FDA has approved Moderna's RSV vaccine, mResvia, as its second licensed product, aimed at safeguarding older adults against respiratory syncytial virus (RSV). Utilizing the same mRNA platform as their COVID-19 vaccine, Spikevax, Moderna CEO Stéphane Bancel highlights the platform's strength and adaptability. RSV poses significant risks, particularly to infants and the elderly, with thousands hospitalized and fatalities annually.

Moderna's vaccine, arriving a year after competitors', distinguishes itself with pre-filled syringe packaging, enhancing efficiency and minimizing administration errors. In a Phase 3 trial, mResvia demonstrated an 83.7% efficacy against RSV-induced lower respiratory tract disease, marking a significant advancement in public health protection. Read more from STAT News here.